@article{ac4cec4fac964b15acdc3b0f8c2db13e,
title = "Hard targets for a second skeleton: therapeutic horizons for fibrodysplasia ossificans progressiva (FOP)",
keywords = "ACVR1, Activin A, bone morphogenetic protein receptors, fibrodysplasia ossificans progressiva, heterotopic endochondral ossification, hypoxia",
author = "Kaplan, {Frederick S.} and Pignolo, {Robert J.} and {Al Mukaddam}, {Mona M.} and Shore, {Eileen M.}",
note = "Funding Information: This work was supported in part by the International Fibrodysplasia Ossificans Progressiva Association (IFOPA), the Center for Research in FOP and Related Disorders, the Ian Cali Endowment for FOP Research, the Whitney Weldon Endowment for FOP Research, the Ashley Martucci FOP Research Fund, the Isaac and Rose Nassau Professorship of Orthopaedic Molecular Medicine (to FSK), the Cali-Weldon Professorship of FOP Research (to EMS), the Ian Cali FOP Clinical Scholarship (to MMA), the Kogod Professorship in Geriatrics, and the National Institutes of Health (NIH R01-AR41916).",
year = "2017",
month = apr,
day = "3",
doi = "10.1080/21678707.2017.1304211",
language = "English (US)",
volume = "5",
pages = "291--294",
journal = "Expert Opinion on Orphan Drugs",
issn = "2167-8707",
publisher = "Informa Healthcare",
number = "4",
}